Study summary

Treatment before surgery doubled time without relapse

GOLP trial · 178 people, phase 2-3, randomized · Published March 2026, New England Journal of Medicine

18.0 mowithout relapse with treatment before surgery, vs 8.7

What was tested

Chemotherapy (gemcitabine-oxaliplatin) with toripalimab and lenvatinib before surgery, against surgery first, for high-risk intrahepatic cholangiocarcinoma that can be removed.

What they found

Median event-free survival was 18.0 vs 8.7 months.
79% vs 61% were alive at 2 years, though this did not yet meet the strict significance bar.
Serious side effects occurred in 28% during pre-surgery treatment.

What it means

A likely shift toward treatment before surgery for high-risk tumors inside the liver. The trial was in China; confirmation elsewhere is needed.

N Engl J Med, via PubMed ↗ ← Back to the outlook

Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.